Villamañan L, Martínez-Escardó L, Arús C, Yuste VJ, Candiota AP. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. Int J Mol Sci. 2021 Mar 26;22(7):3453. doi: 10.3390/ijms22073453. PMID: 33810611; PMCID: PMC8036897.
García-Pardo J, Novio F, Nador F, Cavaliere I, Suárez-García S, Lope-Piedrafita S, Candiota AP, Romero-Gimenez J, Rodríguez-Galván B, Bové J, Vila M, Lorenzo J, Ruiz-Molina D. Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease. ACS Nano. 2021 May 25;15(5):8592-8609. doi: 10.1021/acsnano.1c00453. Epub 2021 Apr 22. PMID: 33885286; PMCID: PMC8558863.
Calero-Pérez P, Wu S, Arús C, Candiota AP. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses. Cancers (Basel). 2021 May 28;13(11):2663. doi: 10.3390/cancers13112663. PMID: 34071393; PMCID: PMC8199490.
Pérez RF, Tejedor JR, Santamarina-Ojeda P, Martínez VL, Urdinguio RG, Villamañán L, Candiota AP, Sarró NMV, Barradas M, Fernandez-Marcos PJ, Serrano M, Fernández AF, Fraga MF. Conservation of Aging and Cancer Epigenetic Signatures across Human and Mice. Mol Biol Evol. 2021 Jul 29;38(8):3415-3435. doi: 10.1093/molbev/msab112. Erratum in: Mol Biol Evol. 2021 Dec 9;38(12):5836. PMID: 33871658; PMCID: PMC8321527.